MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced the amendment and exchange (the “Exchange”) of the Series A warrants issued pursuant to the Securities Purchase Agreement dated June 13, 2019 (“SPA”) with the holders of all outstanding Series A warrants.
Pursuant to the Exchange, the parties agreed to remove certain restrictive covenants under the warrants and the SPA, giving the company greater flexibility to raise funds consistent with its growth strategy and long-term value creation for patients and shareholders.
As part of the Exchange, all the Series A warrants were exchanged for approximately 22 million shares of Ocugen’s common stock and non-interest-bearing unsecured notes in the aggregate principal amount of $5.625 million.
Refer to the Form 8-K filed with the Securities and Exchange Commission, including the agreements filed as exhibits thereto, for complete information regarding the Exchange.
“The successful completion of the warrant exchange addresses our outstanding capital structure overhang. We believe this transaction benefits our stockholders and the Company by creating a cleaner balance sheet and removing the restrictive provisions that were negatively impacting our ability to raise additional funds to support progression of our strong pipeline,” said Sanjay S. Subramanian, Chief Financial Officer of Ocugen.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.